SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is surging amid news of a $5B financing deal, unlocking significant capital for AI data centers and eliminating shareholder dilution concerns, which has sparked a short squeeze frenzy. The community is buzzing about potential hyperscaler partnerships and upgraded price targets, fueling speculation of a continued rally. With high short interest and positive catalysts, APLD is gaining attention as a key player in the AI infrastructure buildout.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is surging due to a strategic partnership focused on developing quantum-resistant chips for U.S. defense applications, fueling speculation about lucrative government contracts. The community is buzzing about the company's growth potential and comparing it to other players in the quantum computing space, with some investors believing LAES is undervalued and predicting a significant climb.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is gaining traction as community members express excitement, referencing an imminent listing on Moonshot and calling for others to "RAGE" harder. Fueling the hype, some are alluding to potential breakouts and increased liquidity, while others point to the project's roots in OG internet meme culture. The community's focus remains on strong community building and promoting the idea of everyone making it.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as chatter increases around a potential short squeeze, with the community noting high short interest and open call option volume. Recent developments, including a major financial endorsement and increased stake from Alphabet Inc., have boosted optimism. Discussions also involve TeraWulf's shift towards AI and high-performance computing, similar to peers in the sector.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the imminent ticker change to NKLR following its merger with Terra Innovatum, a micro-modular nuclear reactor developer; the change is expected to occur soon. Community members are excited about the potential, drawing comparisons to OKLO and highlighting the growing demand for nuclear energy. Discussions also include the stock's valuation relative to its peers and expectations for increased volume and volatility post-ticker change.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is trending as silver prices approach multi-decade highs, sparking discussions about a potential breakout. Community members are actively discussing the possibility of a short squeeze and the impact of supply deficits on prices. Some analysts point to a long-term cup and handle formation, suggesting a bullish outlook, while others debate potential pullbacks and profit-taking opportunities.

One and one Green Technologies. Inc - Ordinary Shares - Class A

YDDL is trending due to its recent IPO and subsequent volatile price action, with the stock experiencing significant gains and drops. The community is actively discussing its low float, high insider ownership, and potential for both further gains and significant losses, with some expressing concerns about it being a pump and dump. Some traders are also looking at other AI and Green Tech names like $APLD and $HIVE.

Zoracles

Zoracles (ZORA) is trending following its recent listing on Robinhood, leading to increased exposure and new investors. The community is actively discussing its potential within the BASE ecosystem and drawing comparisons to other social media platforms.  Many are anticipating further gains and upward momentum, while some caution against potential pullbacks.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as community members discuss its potential breakout and growing institutional attention. Some see it as the next Palantir, fueled by the AI infrastructure wave, while others point to strong call volume and potential short squeeze dynamics. Discussions also highlight UiPath's strategic shift towards agentic AI and partnerships with major tech players.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders debate market manipulation and the impact of potential tariffs, with some expressing concerns over valuations and debt sustainability. Community discussions revolve around government shutdowns, peace deals, and their seemingly counterintuitive effects on market behavior, questioning the influence of market makers and options cycles. Despite a slight dip, many anticipate a continued rally, while others foresee a significant correction, driven by overbought conditions and various economic uncertainties.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

Equity

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Buy Rating for Larimar Therapeutics Backed by Promising Gene Therapy Advances for Friedreich's Ataxia

Larimar Therapeutics (LRMR Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville...

Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Futures Flat As Investors Wait For Nvidia Earnings; Ethereum Soars

Futures Flat As Investors Wait For Nvidia Earnings; Ethereum Soars

 US futures are flat, reversing earlier losses, with European bourses and Asian markets all lower as the international...

Larimar Therapeutics initiated with bullish view at Leerink

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Larimar Therapeutics (LRMR, $7.45) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that LRMR's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Larimar Therapeutics (LRMR, $7.57) RSI Indicator left the oversold zone on March 28, 2024

This is a signal that LRMR's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$4.55
Prev Close	$4.82
Open	$4.78
Dividend Yield	0.00%
50-Day Moving Average	$4.00
Beta	1.26
Avg. Volume	3.27M
PE Ratio	-3.09

52-Week High	$9.50
52-Week Low	$1.61
Market Capitalization	$412.55M
EPS (Annual)	-$1.32
Price to Book	2.57
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

LRMR
Larimar Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LRMR News

LRMRLarimar Therapeutics Inc